Printer Friendly

Alzamend Neuro Names McDade to Its Scientific Advisory Board.

M2 PHARMA-July 17, 2019-Alzamend Neuro Names McDade to Its Scientific Advisory Board

(C)2019 M2 COMMUNICATIONS

- US-based Alzamend Neuro, Inc. has appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its scientific advisory board, the company said.

McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research programme that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease.

Currently, Dr. McDade is leveraging his clinical expertise to develop a cross-disciplinary team that combines neuroimaging, clinical evaluations and basic science to better explore and translate work in the use of imaging and fluid biomarkers to better understand the timing and relationship between measures of disease risk and progression.

The goal of this work is to identify better measures and target for interventions and prevention for Alzheimer's disease and has led to over 76 peer-reviewed publications and continuous funding from the NIH for over five years.

McDade is the Associate director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

The DIAN-TU is a global network of families at risk for a genetic form of AD and is pioneering prevention trials for this young-onset form of AD.

As part of this he serves as the Principle Investigator of the DIAN-TU Primary Prevention Study.

He is also the director of the DIAN Expanded Registry (DIAN EXR).

The DIAN EXR is an international research registry for individuals with confirmed or suspected dominantly inherited Alzheimer's disease in their families and for professionals and researchers involved in clinical care and research on DIAD.

These projects will prove critical to advancing the field of Alzheimer disease treatment.

Alzamend is very pleased having Dr. McDade join the company's Scientific advisory board and believes he will greatly assist the company's CEO, Stephan Jackman, to navigate the scientific and regulatory challenges commonly faced by a developmental biotech company as it pursues the commercialisation of its two patented therapeutic solutions for Alzheimer's disease.

Dr. McDade has received several awards and honors in recognition of his work and leadership including the NIH-NIA K23 Training Grant Award and a NIH-NIA UO1 award for the DIAN-TU Primary Prevention Trial.

Additionally, he has been a LRP Recipient and received the Excellence in Clinical Teaching Award and has been on the Best Doctors in St. Louis and in Pittsburgh lists.

Dr. McDade earned his doctorate at Chicago College of Osteopathic Medicine and a B.A. in Psychology from Canisius College. Dr. McDade completed an internship at the University of Illinois College of Medicine in Chicago and his residency at the University of Maryland where he was a chief resident.

Dr. McDade has his certification of Neurology from the American board of Psychiatry and Neurology and Behavioral Neurology from the United Council of Neurologic Subspecialties.

In the US, Alzheimer's disease is the most prevalent form of dementia, estimated to effect over 5.8m adults.

The company's goal is to move two therapeutic technologies out of the research and preclinical testing stages into clinical trials as it works toward commercialisation.

It is projected that by the year 2050, one in three seniors will have AD or another form of dementia and the disease may affect as many as 88m adults if a cure is not found.

Alzheimer's disease is one of the costliest chronic diseases in the United States and the 2019 economic impact to society was USD 293bn.

The company recommends its shareholders and any interested parties read its public reports and financial statements filed with the Securities and Exchange Commission for further information.

Alzamend Neuro, Inc. is a Delaware corporation with its corporate headquarters in the State of Florida. The mission of Alzamend Neuro is to support the full product development life cycle of treatment and cures for Alzheimer's driven by the belief that strong support of research is the foundation for true innovation.

The company is providing current hope through the commercialization of existing patented intellectual property and know-how while simultaneously funding future hope through advanced research and development.

Alzamend Neuro's underlying goal is to get a treatment or cure for Alzheimer's to market at a reasonable cost as quickly as possible. Far too many suffer daily, patients and caretakers alike, from the burden created by the nation's 6th leading cause of death and 'most feared disease'.

The vision of Alzamend Neuro has been to license CAO22W, the patented mutant peptide for use in immunotherapy and LiProSal, a lithium-based ionic cocrystal oral therapy for patients that have long suffered with the effects of AD from the University of South Florida.

There are no profound treatments for Alzheimer's.

With CAO22W and LiProSal, the company is very hopeful that Alzamend can change that.

It is one of the company's strategic goals to support the continuing research by the teams at the USF Health Byrd Alzheimer's Institute and other USF Health Colleges to develop and commercialise their results into meaningful solutions.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 17, 2019
Words:842
Previous Article:Avrobio Eyes USD 100m Raise from Common Stock Offering.
Next Article:Verm Publishes New Study Demonstrating Overa's Greater Sensitivity in Detecting Ovarian Cancer Compared with ROMA, HE4 + CA125, and CA125 Alone.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |